Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium
Objective Inflammation drives cardiovascular disease in rheumatoid arthritis (RA). Treatment with tofacitinib, a JAK1/JAK3 inhibitor, is associated with increased cardiovascular events in patients with RA. Here, we determined its effects on cytokine production during interactions between immune cell...
Saved in:
Main Authors: | Aliki Zavoriti, Pierre Miossec |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11790 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
by: Martina Morelli, et al.
Published: (2018-01-01) -
Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function
by: Elisa Arribas-Rodríguez, et al.
Published: (2025-06-01) -
Endothelium-Derived Hyperpolarizing Factor and Vascular Function
by: Muhiddin A. Ozkor, et al.
Published: (2011-01-01) -
Administration of PDE4 Inhibitors Suppressed the Pannus-Like Inflammation by Inhibition of Cytokine Production by Macrophages and Synovial Fibroblast Proliferation
by: Katsuya Kobayashi, et al.
Published: (2007-01-01) -
Diabetic Endothelium Dysfunction, Cardiovascular Complications, and Therapeutics
by: Yunzhou Dong, et al.
Published: (2016-01-01)